Regeneron Pharmaceuticals Inc (REGN) Receives $461.51 Consensus Price Target from Analysts

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have earned a consensus rating of “Hold” from the thirty analysts that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $458.12.

Several equities analysts have weighed in on the company. Guggenheim reaffirmed a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Citigroup reaffirmed a “buy” rating and issued a $480.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $491.00 to $479.00 and set a “market perform” rating for the company in a report on Thursday, November 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $425.00 price objective (down from $473.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of REGN. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in shares of Regeneron Pharmaceuticals by 16.1% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 65,862 shares of the biopharmaceutical company’s stock valued at $24,761,000 after buying an additional 9,157 shares during the last quarter. Pin Oak Investment Advisors Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $152,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $561,000. Slow Capital Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $555,000. Finally, Halsey Associates Inc. CT grew its position in shares of Regeneron Pharmaceuticals by 8.4% in the 4th quarter. Halsey Associates Inc. CT now owns 16,347 shares of the biopharmaceutical company’s stock valued at $6,146,000 after buying an additional 1,266 shares during the last quarter. 64.67% of the stock is owned by institutional investors and hedge funds.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $9.11 during midday trading on Tuesday, reaching $323.04. The company’s stock had a trading volume of 822,556 shares, compared to its average volume of 1,140,000. The firm has a market cap of $34,710.00, a PE ratio of 31.30, a PEG ratio of 1.04 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. Regeneron Pharmaceuticals has a 52-week low of $313.53 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.04 EPS. equities research analysts expect that Regeneron Pharmaceuticals will post 19.2 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals Inc (REGN) Receives $461.51 Consensus Price Target from Analysts” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/21/regeneron-pharmaceuticals-inc-regn-receives-461-51-consensus-price-target-from-analysts.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply